Systematic review of immunogenicity and duration of immunity of currently licensed pertussis wP vaccines in children

Página do item simplificado
dc.creatorBagattini, Ângela Maria
dc.creatorRosa, Michelle Quarti Machado da
dc.creatorSilveira, Martha Silvia Martinez
dc.creatorPolicena, Gabriela Moreira
dc.creatorCoelho, Lara Esteves
dc.creatorLuz, Paula Mendes
dc.creatorRussell, Louise B.
dc.creatorToscano, Cristiana Maria
dc.date.accessioned2024-12-06T14:17:00Z
dc.date.available2024-12-06T14:17:00Z
dc.date.issued2022
dc.description.abstractBackground: Currently recommended whole cell pertussis (wP) vaccination schedule for children includes a 3-dose primary schedule, and at least one booster dose. When estimating the impact of additional strategies to reduce pertussis burden through modelling, duration of immunity conferred by childhood immunization is among the parameters models are most sensitive to. We aim to assess the duration of immunity of currently available wP vaccines in children and the additional protection conferred by booster doses. Methods: We conducted a systematic review of published studies of current commercially available vaccines indexed in Medline, Embase, Web of Science, Lilacs, SciELO and Central until September 2021. We included clinical trials, observational longitudinal, and cross-sectional studies. Citation screening, data extraction, and risk of bias and methodological quality assessment were done in duplicate by independent reviewers, following the study protocol registered in PROSPERO. Studies were included if they reported primary data on the protection, immunity, or duration of immunity conferred by ≥3 doses of wP vaccine in healthy children, without restriction to time or location of the study. Outcomes included clinical events or serological evidence of protection. Results: We included 12 studies conducted from 2007-2020 with heterogeneous methodological quality. Studies report on 5 of the 18 currently available wP vaccines in use. After primary immunization, geometric mean concentration (GMC) of anti-pertussis toxin ranged from 9.1 EU/mL (95% confidence intervals [CI]: 8.1-10.2) to 50.9 (95%CI: 45.9-56.4). Prior to the 1st booster, GMC titers were low ranging from 4.7 to 10 EU/mL, and after the 1st booster averaged around 42 EU/mL. Conclusions: The limited available evidence on immunogenicity of currently available wP vaccines reinforces the need for booster doses and suggests that the duration of wP immunity is short, probably <5 years. This is important information for vaccination policy makers, investigators and modelers. PROSPERO registration: CRD42018107309
dc.identifier.citationBAGATTINI, Angela M. et al. Systematic review of immunogenicity and duration of immunity of currently licensed pertussis wP vaccines in children. Gates Open Research, Washington, v. 6, e101, 2022. DOI: 10.12688/gatesopenres.13661.1. Disponível em: https://gatesopenresearch.org/articles/6-101. Acesso em: 2 dez, 2024.
dc.identifier.doi10.12688/gatesopenres.13661.1
dc.identifier.issne- 2572-4754
dc.identifier.urihttp://repositorio.bc.ufg.br//handle/ri/26069
dc.language.isoeng
dc.publisher.countryEstados unidos
dc.publisher.departmentInstituto de Patologia Tropical e Saúde Pública - IPTSP (RMG)
dc.rightsAcesso Aberto
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectSystematic review
dc.subjectImmunogenicity
dc.subjectPertussis vaccine
dc.subjectWhole-cell
dc.subjectChildren
dc.subjectDuration of protection
dc.titleSystematic review of immunogenicity and duration of immunity of currently licensed pertussis wP vaccines in children
dc.typeArtigo

Arquivos

Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
Artigo - Ângela Maria Bagattini - 2022.pdf
Tamanho:
1.81 MB
Formato:
Adobe Portable Document Format
Baixar
Licença do Pacote
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Baixar

Coleções

IPTSP - Artigos publicados em periódicos